SPONSOR
Opus Genetics, Inc
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Conditions studied: ARBBVMDAutosomal-Dominant BestrophinopathyBest Vitelliform Macular DystrophyLCA5
NCT07185256 Phase 1, Phase 2
Recruiting
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
ARB
NCT05616793 Phase 1, Phase 2
Recruiting
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
LCA5